Pharmacokinetics of tenofovir during pregnancy and postpartum

HIV Medicine

Volumn 16, Issue 8, 2015, Pages 502-511

  Best, B M ^a   Burchett, S ^b   Li, H ^c   Stek, A ^d   Hu, C ^e   Wang, J ^f   Hawkins, E ^g   Byroads, M ^h   Watts, D H ⁱ   Smith, E ^j   Fletcher, C V ^k   Capparelli, E V ^a   Mirochnick, M ^l   Aweeka, Francesca ^aa   Chotivanich, Nantasak ^aa   Cressey, Tim Roy ^aa   Frenkel, Lisa M ^aa   Gupta, Amita ^aa   Jennings, Amy ^aa   Jourdain, Gonzague ^aa   Kreitchmann, Regis ^aa   Patel, Rita ^aa   Rungruengthanakit, Kittipong ^aa   Shapiro, David ^aa   Sukrakanchana, Pra ornsuda ^aa   Kovacs, Andrea ^m   Homans, James ^m   Spencer, LaShonda ^m   Kramer, Francoise ^m   Buschur, Shelley ⁿ   Hammill, Hunter ⁿ   Paul, Mary E ⁿ   McMullen Jackson, Chivon ^o   Melvin, Ann ^p   Venema Weiss, Corry ^p   Lane, Jenna ^p   Hitti, Jane ^p   Knapp, Katherine ^p   Edwin Thorpe, E T ^p   Utech, L Jill ^p   Sublette, Nina ^p   Wara, Diane ^q   Cohan, Deborah ^q   Tilton, Nicole ^r   Vachon, Mary Elizabeth ^r   Baig, Mirza Mahboobullah ^r   Purswani, Murli Udharam ^r   Gutierrez, Jenny ^r   Luzuriaga, Katherine ^s   Cormier, Sharon ^s   McManus, Margaret ^s   Hull, Andrew ^t   Caffery, Mary ^t   Norris, Kimberly ^t   Spector, Stephen A ^t   Keller, Margaret A ^u   Ballagh, Susan ^u   Hayes, Judy ^u   Gonzalez, Yolanda ^u   Barr, Emily ^v   Kennedy, Tara ^v   Katai, Alisa ^v   Wallace, Jenna ^v   McAuley, James B ^w   Cejtin, Helen ^w   McNichols, Maureen ^w   Schmidt, Julie ^w   Watson, Douglas ^x   Ference, Judy ^x   Hilyard, Corinda ^x   Crain, Marilyn ^y   Simpson, Tina Y ^y   Tita, Alan T N ^y   Febo, Irma L ^z   Zorrilla, Carmen D ^z   Tamayo Agrait, Vivian ^z   Santos, Ruth ^z   more..

^a RADY CHILDREN'S HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^g SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^h FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

ⁱ EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^j NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^k UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^l BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁿ Texas Children's Hospital CRS   (United States)

^o SEATTLE CHILDREN S HOSPITAL   (United States)

^p UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^q UNIVERSITY OF CALIFORNIA   (United States)

^r Bronx Lebanon Hospital IMPAACT CRS   (United States)

^s Western New England Maternal Pediatric Adolescent AIDS CRS   (United States)

^t UNIVERSITY OF CALIFORNIA   (United States)

^u HARBOR UCLA MEDICAL CENTER   (United States)

^v 5052 University of Colorado Denver NICHD CRS   (United States)

^w Jr Hospital of Cook County   (United States)

^x UNIVERSITY OF MARYLAND   (United States)

^y UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^z UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^aa NONE

more..

Author keywords

Antiretrovirals; HIV; Pregnancy; Prevention of perinatal transmission; Tenofovir

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; BILIRUBIN; CREATININE; EMTRICITABINE; LOPINAVIR PLUS RITONAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIRTH WEIGHT; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG HALF LIFE; DRUG MONITORING; ELIMINATION RATE CONSTANT; FEMALE; FETOMATERNAL TRANSFUSION; GESTATIONAL AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACRIMAL DUCT OCCLUSION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MATERNAL PLASMA; MAXIMUM PLASMA CONCENTRATION; MONGOLIAN SPOT; ORAL CLEARANCE; PARVOVIRUS INFECTION; PLASMA CONCENTRATION-TIME CURVE; PREGNANCY; PREGNANT WOMAN; PRENATAL EXPOSURE; PRIORITY JOURNAL; PUERPERIUM; SECOND TRIMESTER PREGNANCY; STEADY STATE; THIRD TRIMESTER PREGNANCY; TIME TO MAXIMUM PLASMA CONCENTRATION; UMBILICAL CORD BLOOD; VESICOURETERAL REFLUX; VIRUS LOAD; VOLUME OF DISTRIBUTION; ADOLESCENT; CLINICAL TRIAL; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; METABOLISM; MULTICENTER STUDY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD; PROSPECTIVE STUDIES; TENOFOVIR; YOUNG ADULT;

EID: 84938744228     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12252     Document Type: Article

References (16)

1. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf (accessed 9 July 2013).
2. Buckoreelall K, Cressey TR, King JR. Pharmacokinetic optimization of antiretroviral therapy in pregnancy. Clin Pharmacokinet 2012; 51: 639-659.
3. Cao Y, Han Y, Xie J etal. Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study. BMC Infect Dis 2013; 13: 301.
4. Rasmussen TA, Jensen D, Tolstrup M etal. Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. PLoS ONE 2012; 7: e32445.
5. Delahunty T, Bushman L, Fletcher CV. Sensitive assay for determining plasma tenofovir concentrations by LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 830: 6-12.
6. Delahunty T, Bushman L, Robbins B etal. The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 1907-1914.
7. ® [package insert]; 2003.
8. Colbers AP, Hawkins DA, Gingelmaier A etal. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. AIDS 2012; 27: 739-748.
9. Krauer B, Krauer F, Hytten FE. Drug disposition and pharmacokinetics in the maternal-placental-fetal unit. Pharmacol Ther 1980; 10: 301-328.
10. Benaboud S, Hirt D, Launay O etal. Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women. Antimicrob Agents Chemother 2012; 56: 857-862.
11. Hirt D, Ekouevi DK, Pruvost A etal. Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2). Antimicrob Agents Chemother 2011; 55: 2961-2967.
12. Hirt D, Urien S, Ekouevi DK etal. Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109). Clin Pharmacol Ther 2009; 85: 182-189.
13. Flynn PM, Mirochnick M, Shapiro DE etal. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants. Antimicrob Agents Chemother 2011; 55: 5914-5922.
14. Best BM, Mirochnick M, Capparelli EV etal. Impact of pregnancy on abacavir pharmacokinetics. AIDS 2006; 20: 553-560.
15. Moodley J, Moodley D, Pillay K etal. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 1998; 178: 1327-1333.
16. Wang Y, Livingston E, Patil S etal. Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus-infected pregnant women and their neonates: an AIDS clinical trials group study. J Infect Dis 1999; 180: 1536-1541.